Cargando…
Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability
Osteoporosis is a disease that reduces bone mass and microarchitecture, which makes bones fragile. Postmenopausal osteoporosis occurs due to estrogen deficiency. Raloxifene is a selective estrogen receptor modulator used to treat postmenopausal osteoporosis. However, it has a low bioavailability, wh...
Autores principales: | Yang, Shu-Jyuan, Chang, Chih-Hao, Young, Tai-Horng, Wang, Chung-Hao, Tseng, Tzu-Hao, Wang, Man-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387319/ https://www.ncbi.nlm.nih.gov/pubmed/35975329 http://dx.doi.org/10.1080/10717544.2022.2111479 |
Ejemplares similares
-
Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene
por: Patel, B. Divyakant, et al.
Publicado: (2012) -
Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability
por: Kushwaha, Anand Kumar, et al.
Publicado: (2013) -
Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers
por: Murthy, Aditya, et al.
Publicado: (2020) -
Enhanced Bioavailability of Dihydrotanshinone I–Bovine Serum Albumin Nanoparticles for Stroke Therapy
por: Ren, Yanru, et al.
Publicado: (2021) -
Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement
por: Wang, Zaihua, et al.
Publicado: (2018)